NewTimeSpace News: The Hong Kong IPO subscription for Eastroc Beverage (Group) Co., Ltd. (09980.HK) is set to close tomorrow (January 29). The company's maximum offer price for this issuance is HK$248 per share, with an entry fee of approximately HK$25,050.11 per board lot. As per the latest statistics, the total margin financing capital received amounts to HK$11.751 billion.
GON Technology (02768.HK) has launched its H-share offering and is expected to list on the Hong Kong Stock Exchange in February 2026. With a dual-core business layout of "new chemical materials + healthcare", the Company ranks among the top players in China's organic polymer modified materials industry in the chemical sector, and has achieved vertical integration by extending upstream into polystyrene production. In the healthcare sector, it entered the gelatin and collagen industry through the acquisition of Dongbao Biotechnology. The Company has recorded a 19.6% compound annual growth rate (CAGR) in revenue over the past three years. However, its profitability has fluctuated significantly due to raw material price volatility, R&D investments and non-recurring gains.
NewTimeSpace News: According to information released by the Stock Exchange of Hong Kong Limited (HKEX), Shenzhen Woer Heat-Shrinkable Material Co., Ltd. (002130.SZ) passed the listing hearing of HKEX on January 27. China Securities Co., Ltd. International and China Merchants Securities Co., Ltd. International serve as joint sponsors. A global leader in the heat-shrinkable materials industry, the Company held a 20.6% global market share in 2024. It also ranks as the world's third-largest telecom cable manufacturer and China's largest high-speed copper cable manufacturer.
Eastroc Beverage (Group) Co., Ltd. launched its H-share offering on the 26th, with a maximum offer price of HK$248.00 per share and an expected maximum fundraising of approximately HK$9.994 billion. The company is set to list on the main board of the Hong Kong Exchanges and Clearing Limited (HKEX) on February 3, 2026. The highlight of this offering is the introduction of 16 cornerstone investors including the Qatar Investment Authority, Temasek, BlackRock and Sequoia China, who have subscribed for a total of approximately US$640 million (about HK$4.990 billion), accounting for around 49.2% of the issued shares. This listing has provided Eastroc Beverage with a dual A+H financing platform, and whether it can leverage international capital to further consolidate its advantages and expand growth space will be the long-term focus of the market.
IPLUSMOBOT Technology filed for HKEX IPO on Jan 23, 2026, ranking among the global top 5 industrial intelligent mobile robot players by order value. The company posted 2024 revenue of RMB 115 million (+53.2% YoY) and RMB 201 million for 9M 2025, with improving margins but ongoing losses. Backed by ByteDance and Lenovo, it targets R&D and global expansion with the proceeds.
Eastroc Beverage (Group) Co., Ltd. (09980.HK) officially launched its Hong Kong public offering on January 26. It plans to offer a total of approximately 40.89 million new H - shares globally, 10% of which are allocated to the Hong Kong public offering. The offer price is set at HK$248 per share, with a trading lot of 100 shares, resulting in an entry fee of about HK$25,050.11. As the leading functional beverage enterprise in China by sales volume, the company boasts over 4.3 million terminal sales outlets. Its shares are expected to start trading on the main board of the Hong Kong Exchanges and Clearing Limited (HKEX) on February 3.
Beijing Deltaphone Technology Co., Limited re-submitted its listing application to the Hong Kong Exchanges and Clearing Limited (HKEX) on January 20, with Sunny Fortune Capital Limited acting as the sole sponsor. As a national-level specialized, sophisticated, distinctive and innovative "Little Giant" enterprise, the company focuses on providing integrated AIoT production optimization software solutions for key industries such as energy and manufacturing, ranking third in market share in the energy sector. The company's revenue has maintained steady growth, reaching RMB 525 million in fiscal year 2024, yet it remains in a period of strategic loss due to high R&D investment. Boasting a strong shareholder lineup with the participation of "national team" investors and industrial capital including CICC CTS Logistics Investment, Shenzhen Venture Capital and Bank of Communications Investment, the company's post-investment valuation has risen to approximately RMB 2.35 billion. Benefiting from policy support and the industrial digitalization trend, the AIoT solution market where the company operates has broad prospects, providing sustained impetus for its future growth.
Shenzhen Woke Technology Co., Ltd. submitted a listing application to the Hong Kong Exchanges and Clearing Limited (HKEX) on the 20th. Its core business is to sell 3C accessories and small home appliances to the Southeast Asian market under its own brands via a full-link digital platform. The company holds a leading position in the cross-border 3C accessories market in Indonesia and has built an omnichannel sales network connecting more than 40,000 retail stores across Southeast Asia.Its business model is underpinned by the "own brand + omnichannel sales + digital supply chain" framework, aiming to enhance operational efficiency in the fragmented market. Financial data shows that the company has achieved steady revenue growth, yet constrained by industry characteristics, it exhibits the trait of "high revenue with low net profit", with its net profit margin remaining at a low level.The proceeds raised from this listing will be mainly used to strengthen the supply chain and warehousing network, expand marketing channels, and upgrade the brand's digital capabilities, so as to consolidate its market position in the fast-growing Southeast Asian market.
Guoyi Medical Technology has formally submitted an application for a Main Board listing on the Hong Kong Stock Exchange. As the leader of China's third-party SPD solution market, the company held a 29.2% market share in 2024. Financial data shows that its net profit surged 368% year-on-year to RMB 57.585 million in 2024. The company's business covers 116 hospitals across 13 provinces in China, with shareholders including iFlytek Venture Capital and Xinli Capital.
PrimeGenX Therapeutics Co., Ltd. formally submitted an application to list on the Main Board of The Stock Exchange of Hong Kong Limited on January 21, 2026, with CITIC Securities and CMBC Capital acting as joint sponsors. The company is a biotech firm specializing in the immune-inflammation field. Its core strategy is to develop differentiated therapies for chronic inflammatory diseases through innovative design and precise local delivery technologies. Its key late-stage core product is PuMeiXiTiNi (PG-011) for treating atopic dermatitis and allergic rhinitis.
Shandong Huawutang Cosmetics Co., Ltd., the entity behind the domestic beauty brand Dream Garden, recently submitted a listing application to the Hong Kong Exchanges and Clearing Limited (HKEX). According to the Frost & Sullivan report, based on retail sales in 2024, the company ranks first among domestic brands in China across three categories: body lotion, body scrub, and facial cleansing mousse. The prospectus shows that the company recorded revenue of RMB 1.895 billion in the first nine months of 2025, representing a year-on-year increase of 76.7%, with a net profit of RMB 125 million during the same period. Notably, revenue from its hair care segment surged by 496.1% year-on-year, emerging as a new growth driver.
Hangzhou Yodosmart Automotive Technology Co., Ltd. formally submitted a listing application to the HKEx Main Board on January 19, 2026. The company is a leading domestic supplier in China's intelligent connected vehicle solutions industry. According to Frost & Sullivan, it is China's third-largest domestic in-vehicle communication solution supplier (7% market share), and its 4G in-vehicle communication solution ranks first in shipment volume among domestic suppliers (7.8% market share). Its clients cover six of China's top ten OEMs in 2024. Financially, the company has demonstrated rapid revenue growth and stable profitability, with gross margins ranging between 23.5% and 27.4% from 2023 to the first nine months of 2025. The proceeds from this IPO are intended for product innovation, industrial base construction (including the new Wuhu factory), technological mergers and acquisitions, and working capital.
Busy Ming Group Co., Ltd. (01768.HK) officially launched its initial public offering (IPO) on January 20, 2026. The offering price is set in the range of HK$229.6 to HK$236.6 per share, with a maximum expected fundraising amount of approximately HK$3.336 billion.Leveraging its discount retail model and full franchise system, the company has expanded its store network rapidly from around 6,585 to nearly 20,000 in less than two years, among which approximately 59% are located in the sinking market, cementing its position as the industry leader. Its financials have registered exponential growth, with revenue hitting RMB 39.344 billion in 2024.This IPO has garnered strong backing from eight top-tier cornerstone investors including Tencent, Temasek, BlackRock and Fidelity, with a combined subscription of approximately HK$1.52 billion.
Zenitar Biotech recently submitted its listing application to the Hong Kong Stock Exchange. The company is a late-stage clinical biotechnology company with core products Flunotinib Maleate and Pruinostat Mesylate having entered registration Phase III clinical trials. The prospectus shows that the company has not yet generated operating revenue, with accumulated losses reaching RMB 211 million over the past two years.
ROBOTPHOENIX recently submitted its listing application to the Hong Kong Stock Exchange again. According to Frost & Sullivan, by 2024 revenue, the company is the fifth-largest domestic supplier of industrial robot solutions for China's light industry sector. The prospectus shows that the company's 2024 revenue was RMB 268 million, but it continued to incur losses during the reporting period, with accumulated losses reaching RMB 366 million from 2022 to the first three quarters of 2025.
BOCO Electronics recently submitted its listing application to the Hong Kong Stock Exchange. According to the Frost & Sullivan report, by 2024 revenue, the company is the largest high-performance computing server power supplier in the China market, with a market share of 18.9%. The prospectus shows that the company's revenue in the first nine months of 2025 reached RMB 751 million, representing a 126% year-over-year increase, with profit during the period of RMB 76.11 million. Its overseas business revenue proportion has increased to 34.8%.
